Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10.
Published July 29, 2026 · Recall initiated: June 30, 2026
Summary
FDA records drug Class III recall D-0736-2026, published July 29, 2026 and initiated June 30, 2026. Recalling firm: Ascend Laboratories, LLC; Status: Ongoing; Reported quantity: 2,717 cartons; Lot: Lot: 25141584, Exp 4/30/2027. Class III means the product is not likely to cause adverse health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
What to do
Voluntary: Firm initiated · Letter
Get an email if DABIGATRAN ETEXILATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DABIGATRAN ETEXILATE
- Manufacturer
- Ascend Laboratories, LLC
- Distributor
- USA Nationwide
- UPC
- 0309047253043
- Lot
- Lot: 25141584, Exp 4/30/2027.
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories,July 29, 2026
- FDAGlycopyrrolate Oral Solution, 1 mg/5 mL, delivers 5 mL, Rx only, Pkg: Precision Dose, Inc, S. Beloil, ILJuly 29, 2026
- FDACetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (AJuly 29, 2026
Questions about this recall
Was Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10. recalled?
Yes. FDA published recall D-0736-2026 on July 29, 2026. Reported hazard: Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DABIGATRAN ETEXILATE. UPC: 0309047253043.